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Summary
Background The high prevalence of actinic keratosis (AK) requires the optimal use
of healthcare resources.
Objectives To gain insight in to the healthcare utilization of people with AK in a
population-based cohort, and the management of AK in a primary and secondary
care setting.
Methods A retrospective cohort study using three complementary data sources was con-
ducted to describe the use of care, diagnosis, treatment and follow-up of patients with
AK in the Netherlands. Data sources consisted of a population-based cohort study
(Rotterdam Study), routine general practitioner (GP) records (Integrated Primary Care
Information) and nationwide claims data (DRG Information System).
Results In the population-based cohort (Rotterdam Study), 69% (918 of 1322) of
participants diagnosed with AK during a skin-screening visit had no previous AK-
related visit in their GP record. This proportion was 50% for participants with
extensive AK (i.e. ≥ 10 AKs; n = 270). Cryotherapy was the most used AK treat-
ment by both GPs (78%) and dermatologists (41–56%). Topical agents were the
second most used treatment by dermatologists (13–21%) but were rarely applied
in primary care (2%). During the first AK-related GP visit, 31% (171 of 554) were
referred to a dermatologist, and the likelihood of being referred was comparable
between low- and high-risk patients, which is inconsistent with the Dutch general
practitioner guidelines for ‘suspicious skin lesions’ from 2017. Annually, 40 000
new claims representing 13% of all dermatology claims were labelled as cutaneous
premalignancy. Extensive follow-up rates (56%) in secondary care were registered,
while only 18% received a claim for a subsequent cutaneous malignancy in 5 years.
Conclusions AK management seems to diverge from guidelines in both primary
and secondary care. Underutilization of field treatments, inappropriate treatments
and high referral rates without proper risk stratification in primary care, com-
bined with extensive follow-up in secondary care result in the inefficient use of
healthcare resources and overburdening in secondary care. Efforts directed to bet-
ter risk differentiation and guideline adherence may prove useful in increasing
the efficiency in AK management.
What’s already known about this topic?
• The prevalence of actinic keratosis (AK) is high and, in particular, multiple AKs are
a strong skin cancer predictor.
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• The high prevalence of AK requires optimal use of healthcare resources.
• Nevertheless, (population based) AK healthcare utilization and management data
are very rare.
What does this study add?
• Although AK-related care already consumes substantial resources, about 70% of the
AK population has never received care.
• Primary care AK management demonstrated underutilization of topical therapies
and high referral rates without proper risk stratification, while in secondary care
the extensive follow-up schedules were applied.
• This inefficient use of healthcare resources highlights the need for better harmo-
nization and risk stratification to increase the efficiency of AK care.
Actinic keratoses (AKs) are erythematous, asymptomatic kera-
totic lesions that usually develop in the second phase of life,
and occur predominately in chronic ultraviolet-exposed skin
of light-skinned individuals.1,2 The prevalence of AKs is high:
in population-based data from the Rotterdam Study (RS) and
the Australian Skin Cancer Cohort it has been estimated that
24% (the Netherlands) to 60% (Australia) of people older
than 50 years have at least one AK.3,4 The likelihood of an
individual lesion to progress to squamous cell carcinoma
(SCC) is < 1% per year.5 However, patients often have multi-
ple AKs indicating cutaneous field dysplasia, which substan-
tially increases their risk of developing skin cancer, mostly
SCC and basal cell carcinoma (BCC). Although these tumours
account for only a few cancer-related deaths,3,6 premalignant
and malignant skin cancers consume substantial health
resources and have an impact on the quality of life.7
Despite the high impact of AK-related care, there is a lack of
empirical evidence on the management of AK. The reasons for
this are that patients do not necessarily seek care for asymp-
tomatic AK, AK is often a clinical diagnosis and thus not captured
in the pathology and cancer registries, and patients can be man-
aged in both primary and secondary care. A single data source is
therefore not sufficient to capture the complete healthcare uti-
lization pathway of this group. A previous study by Kirby et al.
showed a variation in costs for the management of AK within
and between regions, which could not be fully explained by
patient characteristics, and advocated to identify the care path-
ways of patients with AK.8 The objective of this study was to
provide insight in to the management of AKs by describing the
healthcare utilization of people with AK in a population-based
cohort and in the primary care and secondary care settings.
Patients and methods
Study design
To study AK management, a retrospective, multiple database,
descriptive cohort study of population-based data and routine
data of people with AK was conducted (Fig. 1).
Data sources and study population
Population-based cohort: Rotterdam Study
The RS is an ongoing population-based cohort study of nearly
15 000 participants aged 45 years and older from a suburb in
Rotterdam in the Netherlands.9 Between August 2010 and
November 2015, 5517 participants received a full-body skin
examination (FBSE) by dermatologically trained physicians.
Standardized forms were used to document the most common
skin diseases, including AK and categorizing the total body
count into 0, 1–3, 4–9 and ≥ 10 lesions. General practitioner
(GP) records before the RS screening visit of participants with
AK were manually screened for the presence of previous AK
diagnoses (clinical diagnosis by GP or dermatologist, or histo-
logically confirmed), treatments and AK-related follow-up visits.
As participants with extensive AK were advised to consult their
GP, which may have changed their healthcare consumption,
only records before the screening visit were evaluated (Fig. 2).
To assess the total health impact, RS was used to evaluate the
management during all AK-related visits, instead of differentiat-
ing between initial and follow-up visit. Subsequent keratinocyte
cancer (KC) development was obtained by linkage of all RS par-
ticipants with the Dutch Pathology Registry (PALGA), the
nationwide registry of histo- and cytopathology in the Nether-
lands (Data S1; see Supporting Information).10,11
Routine general practitioner records: Integrated Primary
Care Information database
Integrated Primary Care Information (IPCI) is a central
research database with a collection of 23 million electronic
routine patients records from 265 GP practices in the Nether-
lands since 1989.12 To capture both long-term follow-up and
recent common practice, a random sample of 1000 patients
diagnosed with AK was selected based on a free text algorithm
equally divided over 2009/2010 and 2012/2013 (Data S1;
see Supporting Information). Patients were eligible if the GP
mentioned AK in the differential diagnosis, AK was confirmed
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in a histopathological report or AK diagnosis was confirmed
by a medical specialist. For eligible patients, the treatment at
first GP encounter was extracted, and for those with non-AK-
specific treatments, such as antibiotics, treatment during the
second consultation was included. For the cohort 2009/2010,
the frequency of documented BCC and SCC during the
remaining follow-up period was assessed.
Nationwide hospital claims: DRG Information System
database
Outpatient care for patients with AK was further evaluated
using the national healthcare insurance data from the DRG
Information System (DIS). To obtain a perspective on the scope
of the problem, data were extracted from opendisdata.nl,
Fig 1. This research was conducted using three complementary databases and shows a visual record of the position in health care of the data
collection of each data source for this research. AK, actinic keratosis; DIS, DRG Information System; GP, general practitioner; IPCI, Integrated
Primary Care Information.
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which is an openly accessible source on healthcare insurance
data.13 Health insurance is compulsory for all Dutch residents,
and all activities related to diagnosing or treating patients are
recorded into a DRG package, which results in a healthcare
claim.14 The nationwide DIS database receives and manages
information on healthcare claims but does not contain personal
data. Patients with a dermatologist-based healthcare claim for a
cutaneous premalignancy (code 017) between 2011 and 2015
without previous cutaneous malignancies (code 014) were
included. Data were obtained on registered treatments, follow-
up visits and potential subsequent claims for cutaneous malig-
nancies. As a claim for a ‘cutaneous premalignancy’ can also
include other cutaneous premalignancies, an algorithm was
developed to identify patients with AK based on healthcare pro-
cedures. This algorithm was validated with local (i.e. Erasmus
University Medical Center, Rotterdam) patient records resulting
in a positive predictive value of 93% (Data S1; see Supporting
Information).
Statistical analysis
The primary objective was to describe current clinical practice
and healthcare utilization. No hypothesis testing and sample-
size calculations were therefore performed. All available
data from the RS and DIS were used. For the IPCI data, we
considered that 1000 patients with AK was sufficient to
describe current clinical practice and was feasible with regard
to the time-consuming manual review of medical records.
Complementing the descriptive analyses, we calculated the
relative risk and the 95% confidence interval (CI) for subse-
quent KC risk among RS participants. The v2-test was used to
evaluate the significance level (P = 005) between proportions
for several values among different AK severity categories.
The analyses were performed using SPSS 210 statistical
software (IBM Corp., Armonk, NY, U.S.A.) and SAS 93 statis-
tical software (SAS Institute Inc., Cary, NC, U.S.A.). The
STROBE and RECORD statements were used for reporting the
descriptive analyses.15,16
Results
Population-based cohort: Rotterdam Study
Of the 5517 individuals from the RS who underwent an FBSE,
1510 (27%) were diagnosed with AK. The primary care record
was available in 1322 of 1510 participants (876%); 55% were
male and the mean  SD age was 61  5 years (Table 1).
Diagnosis
Of the 1322 participants with AK and a primary care record,
55% had one to three AKs, 25% had four to nine AKs and
20% had ≥ 10 AKs (Table 1). The retrospective GP record
review of this population-based AK cohort, showed that 918
(69%) participants had never visited a healthcare provider for
their AK before the FBSE (Table 2). Although this decreased
slightly with the number of AKs, 50% of those with ≥ 10 AKs
had never consulted a physician for AK. No substantial differ-
ences in likelihood of having consulted a physician for AKs
were observed across age categories and gender (Data S1
tables; see Supporting Information).
Treatment
Of the 1322 participants, 266 (20%) had a previous AK-related
GP consultation, with 455 visits. No active AK-focused treat-
ment was described in the GP record in 19% of AK-related vis-
its (85 of 455), and in 16% (n = 74) of all first and subsequent
visits the patients were referred to secondary care (Table 3).
Among those with ≥ 10 AKs, the odds of being referred to a
specialist during the first AK-related GP visit were not signifi-
cantly different from those with one to three AKs (19 of 86 vs.
20 of 108; odds ratio 12, 95% CI 062–252, P = 054).
Patients were treated by a GP in 297 of the 455 AK-related
visits (65%), at which cryotherapy was mostly applied (78%,
239 of 297). Among patients only seen by the GP, the pro-
portion of visits during which cryotherapy was applied
Fig 2. Each data source had a slightly different period of data collection. The figure shows the data-collection timeline of each data source. DIS,
DRG Information System; FBSE, full-body skin examination; GP, general practitioner; IPCI, Integrated Primary Care Information; PALGA, the Dutch
Pathology Registry.
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increased significantly with the number of AKs (52% in one
to three AKs to 68% in ≥ 10 AKs, P = 004; Data S1 tables;
see Supporting Information). In 2% of the 297 AK visits dur-
ing which a treatment was given by the GP, a topical AK ther-
apy was prescribed, while other treatments unrelated to AK
(e.g. antibacterial ointments) were prescribed in 14% of visits.
Of the 1322 patients with AK, 251 had at least one previ-
ous dermatology visit with 422 visits (Table 3). No treatment
was given during 52 (12%) visits and in 364 of 422 (86%)
of all visits the patient was treated by the dermatologist; in
the remaining six visits information was missing. Cryotherapy
was the most used treatment (56%, 203 of 364), followed by
field treatment (26%), of which photodynamic therapy was
used during 19 visits. For patients treated by the dermatologist
the proportion of visits during which the field treatment was
selected increased significantly with the number of AKs (20%
in one to three AKs to 32% in ≥ 10 AKs, P = 002; Data S1
tables; see Supporting Information).
Follow-up
Of the 266 individuals with AK seen by the GP, 166 patients
(62%) had no second visit for AK recorded over a median
follow-up time of 28 years (Table 4); although this group
also contains patients referred to the dermatologist. The
remaining 100 patients had 189 subsequent visits for AK,
24% of follow-up visits were within 3 months after the initial
treatment and 22% in the year following the first GP visit.
Among 1322 RS cohort participants with AK, a BCC was
recorded in PALGA among 7% (n = 88) and an SCC in 4%
(n = 50) of participants during a median follow-up period of
28 years (interquartile range 13–44). The risk of any KC
(i.e. not AK-lesion specific) increased from 9% (65 of 724)
for individuals with one to three AKs to 16% (43 of 270) for
those with ≥ 10 AKs. The relative risk of developing a histo-
logically confirmed KC was 30 (95% CI 24–39) for the
group with AK compared with those without AK in the RS
(111 of 1322 vs. 116 of 4193).
Routine general practitioner records: Integrated Primary
Care Information database
Diagnosis
Among the 1000 randomly selected eligible patients who
mentioned AK for the first time in the patient record, 47%
(n = 471) were men and the mean  SD age was 69  12
years (Table 1). Among these 1000 patients, 400 were
included based on correspondence from dermatologists in the
Table 1 Characteristics of the skin screened sample from the
population-based cohort (RS) and a random sample of patients with
AK from the GPs database (IPCI)
Routine GP
records (IPCI) RS
N 1000 1322
Male, n (%) 471 (47) 723 (55)
Age, mean  SD 69  12 61  5
Number of AK, n (%) Described
by GPa,b
Counted
during
FBSE
Described
by GP
during 455
visitsa
1–3 528 (53) 724 (55) 117 (26)
4–9 27 (3) 328 (25) 5 (1)
> 10 2 (02) 270 (20) 0 (0)
Present, without
absolute
numbers
412 (41) 0 (0) 333 (73)
History of cutaneous
keratinocyte
carcinoma, n (%)
325 (25)
Basal cell carcinoma 53 (5) 271 (20)
Squamous cell
carcinoma
23 (2) 69 (5)
Basic characteristics of patients included in hospital claims data
are not available as patient characteristics are not recorded in
claims data on a nationwide level. AK, actinic keratosis; FBSE,
full-body skin examination; GP, general practitioner; IPCI, Inte-
grated Primary Care Information; RS, Rotterdam Study. aBased
on routine GP care, where FBSE is usually not conducted and the
number of AK is usually not explicitly stated in GP records. bTo-
tal number does not add up to 1000 as 31 patients ultimately
did not have AK.
Table 2 Likelihood of actinic keratosis (AK) diagnosis in routine care
among participants with AK detected by skin screening in a
population-based cohort study (Rotterdam Study, RS)
Number of AK diagnosed
during RS FBSE
Total1–3 AK 4–9 AK ≥ 10 AK
AK detection
in skin
screening, n
724 328 270 1322
No routine care
based prior AK
diagnosis, n (%)
556 (77) 226 (69) 136 (50) 918 (69)
Previous routine
care based AK
diagnosis, n (%)
168 (23) 102 (31) 134 (50) 404 (31)
Diagnosis by
GP, n (%)
68 (40) 45 (44) 40 (30) 153 (38)
Diagnosis by
dermatologist,a
n (%)
60 (36) 30 (29) 48 (36) 138 (34)
Diagnosis by both
GP and
dermatologist,
n (%)
40 (24) 27 (26) 46 (34) 113 (28)
FBSE, full-body skin examination; GP, general practitioner. aAs
derived from GP records. If dermatologist correspondence does
not state AK, diagnosis is classified as AK according to the differ-
ential diagnosis of the GP.
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GP record and were not seen by the GP for AK during the
preceding year. The remaining 600 patients had a GP visit
including an AK diagnosis, of which AK Was in the differen-
tial diagnosis by GPs in 554 cases. In 97%, AKs were clinically
diagnosed and 3% were confirmed by histology.
Treatment
Over 60% (n = 341) of the 554 patients with AK in the differ-
ential diagnosis were treated by their GP, predominantly with
cryotherapy (251 of 341, 74%; Table 3), followed by surgery
(8%) and topical treatment (7%). Other medical treatments
(e.g. antibacterial ointments) were prescribed by GPs in 11%
(n = 38) of patients with the first mention of AK in their record.
In 8% (42 of 554) the GP recorded an AK and did not describe
any further treatment or referral suggesting a wait-and-see pol-
icy. One-third (171 of 554) of patients with AK were referred
to the dermatologist at the time of the first clinical diagnosis.
Follow-up
During a median follow-up of 56 years of 486 patients with
a confirmed AK in the 2009/2010 cohort, 69% had a second
GP visit related to cutaneous (pre)malignancies (not AK
specific; Table 4). Subsequent BCCs were recorded among 72
patients (15%) and SCCs among 36 of the 486 patients (7%).
Among the 38 patients who initially received treatments not
indicated for AK, four subsequently received cryotherapy, four
again received treatments not indicated for AK and 30
received no further treatment during follow-up.
Nationwide hospital claims: DRG Information System
Using open source data, 98 435 (13%) of the 768 770 der-
matology-related claims in 2015 were due to cutaneous pre-
malignancies, including AK. Between 2011 and 2015,
200 056 claims of incidental patients with AK without a pre-
vious cutaneous malignancy were identified (Data S1; see Sup-
porting Information).
Treatment
In 22% (44 262 of 200 056) of the first AK-related visits, no
treatment was registered. Of the 155 794 claims that included
a treatment, 41% involved cryotherapy, 13% topical AK treat-
ment, 2% photodynamic therapy, 17% a surgical procedure
(i.e. biopsy or excision) and 26% coagulation or laser therapy
(Table 3).
Table 3 Distribution of treatment modalities for actinic keratosis (AK) by general practitioners (GPs) and dermatologists using three different
datasets
Treatment by GP Treatment by dermatologist
Routine GP records (IPCI) RS RS Hospital claims data (DIS)
GP records, first AK visit
GP records, all
AK-related visits
Dermatologist
correspondence,
all AK-related visits
Claims for cutaneous
premalignancies,
first AK-related visit
Patients, n 554a 266b 251b 200 056
Visits, n 554 455 422 200 056
No treatment (incl. no referral), n (%) 42 (8) 85 (19) 52 (12) 44 262 (22)
Referral, n (%) 171 (31) 67 (15) N/A N/A
Treatment by GP, n (%) 341 (62) 297 (65) N/A N/A
Treatment and subsequent referral 41 (7) 7 (2) – –
Treatment by GP only 300 (54) 290 (64) – –
Missing, n (%) 0 (0) 6 (1) 6 (1) 0 (0)
Type of treatment, n (%) 341 (62) 297 (65)c 364 (86)c 155 794 (78)d
Cryotherapy 251 (74) 239 (78) 203 (56) 64 047 (41)
Topical treatment of AKe 23 (7) 7 (2) 76 (21) 20 908 (13)
Photodynamic therapy – – 19 (5) 3150 (2)
Surgical 28 (8) 12 (4) 43 (12) 26 324 (17)
Other medical treatment of AKf 38 (11) 42 (14) 22 (6) 981 (1)
Otherg 1 (03) 5 (2) 1 (03) 40 384 (26)
Different datasets are not comparable. When methyl aminolaevulinate cream is mentioned, this is not scored since the only indication for this
treatment is as a primer for photodynamic therapy. DIS, DRG Information System; IPCI, Integrated Primary Care Information; N/A, not appli-
cable; RS, Rotterdam Study. aIn 554 of the 1000 patients included from the IPCI GP database, AK was in the differential diagnosis of the GP.
bOf the 1322 participants screened in the RS, 266 had an AK-related visit at the GP and 251 at the dermatologist. cTotal numbers add up to
> 100% as patients may have received multiple treatments for their AK(s). dFor each AK-related visit only the most invasive treatment was
scored. eRelevant treatment of AK: 5-fluorouracil, imiquimod and ingenol mebutate gel. For the hospital claims data this was only registered
if patient picked up their prescribed treatment within 7 days after the outpatient clinic visit. fIncluded in other medical treatment of AK:
nontopical treatment, tretinoin, salicylic acid, ureum, lanette, fucidine, cetomacrogol, diclofenac, antimycotic, antibacterial. gOther treatments
are: laser, coagulation, unknown.
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Follow-up
All 200 056 patients with AK were followed until 31
December 2015, with 517 698 dermatology outpatient clinic
visits. Fifty-six per cent of the 200 056 patients had at least
one dermatology follow-up visit, with a total of 317 642
visits (Table 4). Almost two-thirds of the follow-up visits
were in the first year after initial treatment, with an average
of 18 visits per patient. Thirteen per cent of the 317 642
follow-up visits included a surgical procedure and 17%
cryotherapy.
In the cohort with an initial claim for AK in 2011
(n = 46 415), and thus with the most extended follow-up
time of 5 years, 18% (n = 8390) of the patients had a subse-
quent claim for a cutaneous malignancy.
Discussion
Although AK is a common skin condition that accounts for at
least 10% of all dermatological visits, a substantial proportion
of the general population seems unaware of having AK. In
both primary and secondary care, cryotherapy was most com-
monly used. Field therapy was the second option for derma-
tologists, while GPs only rarely applied these topical therapies.
The number of AKs only modestly increased the likelihood of
having an AK-related GP consultation, while it did not affect
the risk of being referred to secondary care. Follow-up sched-
ules seem to be extensive in secondary care.
This study shows that half of the people with ≥ 10 AKs in
the population-based cohort had no previous consultation. As
GP consultations are mostly patient driven, it is most likely
the result of patients being unaware of having AKs and the
potential increased risk to develop KC. Limited awareness in
the general population implies the potential of underdiagnosis
and undertreatment of AK. Although not all AKs warrant treat-
ment, this does raise concerns with extensive AK (i.e. multiple
AKs or field change).2 As a clinical biomarker of extensive
ultraviolet exposure, we have demonstrated that the number
of AKs correlates with an increased risk of KC, which may
contribute to the growing burden of KC.2,3,17,18 Therefore,
appropriate awareness about AK and its treatment, particularly
for patients with ≥ 10 AKs, is important for both the general
population and GPs, which is also advocated by the US
Preventative Services Task Force.5,19–21 As AKs are often
located on visible skin sites such as the face and scalp, GPs
may have an important role in increasing the awareness of
AKs.3,19,22 Unfortunately, from our data we were unable to
estimate the extent to which the AKs have been noted by GPs.
However, it may be questioned if GPs being proactive about
AKs is feasible, as patients are already bringing multiple prob-
lems to the brief consultations with the GP; therefore, a low-
risk condition such as AK may not be of the highest priority
for either the patient or the GP.23–25
Relatively recently (June 2017) the first Dutch GP guideli-
nes for ‘suspicious skin lesions’ were published, while sec-
ondary care AK-specific guidelines have been available since
2010.19,26,27 This might have affected different (awareness
Table 4 Actinic keratosis (AK)-related healthcare visits and subsequent (pre)malignancies among patients with AK
Database
GP records
Dermatologist records
Routine GP records (IPCI) Rotterdam Study Claims data (DIS)
Patients, n 486d 266 200 056
Follow-up time (years) Median 56, IQR 51–62 Median 28, IQR 13–44 Up to 5 yearse
Follow-up
Number of AK-related follow-up visits
0 149 (31) 166 (62) 87 302 (44)
≥ 1 337 (69)a 100 (38) 112 754 (56)
Visits per period, n (%) N/A 189 visits in 100 patients 317 642 visits in 112 754 patients
<3 months – 46 (24) 101 382 (32)
3–12 months – 42 (22) 86 766 (27)
> 12 months – 94 (50) 129 494 (41)
Unknown – 7 (4) 0 (0)
Cutaneous lesions
Subsequent cutaneous malignancy, n (%) 138 (10) of 1322b 19 178 (11)c
Basal cell carcinoma 72 (15) 88 (7) N/A
Squamous cell carcinoma 36 (7) 50 (4) N/A
DIS, DRG Information System; GP, general practitioner; IPCI, Integrated Primary Care Information; IQR, interquartile range; N/A, not appli-
cable. a486 patients with confirmed AK in the cohort 2009/2010. bAll patients were followed up to mid-2016, independent of the year of
initial treatment. cTotal of patients with one or more skin cancer related GP visits (not AK specific). dCases were identified using linkage with
the Dutch Pathology Registry (PALGA) in the period from the date of skin screening based AK diagnosis until the end of 2015. Median fol-
low-up period for this group is 37 (IQR 13–46). eIncludes patients with a subsequent claim for diagnostic code 0017 for cutaneous malig-
nancy, including basal cell carcinoma, squamous cell carcinoma, (lentigo maligna) melanoma, lymphoma, cutaneous metastatic disease and
other cutaneous malignancies; no further differentiation available. Only the first claim for cutaneous malignancy could be extracted.
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and) management of AK between primary and secondary care.
Cryotherapy was the main treatment modality used by GPs,
and interestingly the number of cryotherapy treatments
significantly increased with more extensive AK. The recently
introduced GP guidelines recommend cryotherapy for five or
fewer AKs, which is comparable with international
guidelines.2,19,28–30 The limited treatment modalities used by
GPs may be a reflection of limited familiarity of GPs with dif-
ferent treatment modalities for AK, possibly because of the
undersupply of dermatology training in both GP specialist
training and continuing medical education programmes in
many countries.31–40 Effective and successful implementation
of the primary care guidelines has the potential to fill this
educational gap in the short term, and may result in the
decreased use of nonindicated treatments (such as antibiotics)
and structuring the use of suitable treatments by GPs. How-
ever, without proper dermatology training for GPs, clinical
guidelines are not sufficient to improve patient care.41 Suffi-
cient education, time and resources are pivotal for the
successful management of AK in primary care.
A substantial proportion of patients with AK were referred
to the dermatologists (38% at the first encounter in primary
care), which was unrelated to the extent of AK. The group of
patients solely referred for AK is already significant with
40 000 new patients being referred to the dermatologists per
year within a population of 17 million inhabitants. However,
this is still a substantial underestimation of the total AK load
in secondary care as this excludes patients who also have cuta-
neous malignancies. Given these large numbers of patients
with AK, AK being managed rather than cured, and overbur-
dening in secondary care, both national and international
guidelines support the concept that the majority of
patients with AK could and should be managed in pri-
mary care.2,19,28,29 Many countries including the Netherlands,
have some level of gatekeeping in access to specialists,
although the extent varies widely between countries.42–45
However, with skin cancer GP education being side-lined in
both a national and an international perspective, successful AK
management (and thus efficient gatekeeping) is compro-
mised.32–34,37–39,46,47 Increasing the familiarity of GPs with
AK management by extending dermatology training for GPs
may increase the likelihood of treating the condition them-
selves, reducing the use of nonindicated treatments (e.g.
antibiotics) and limiting patients entering secondary
care.19,37,40,48,49 Examples of the effect of additional training
can be seen with dedicated and specialized GPs in Australia
and the U.K., where they have a greater role in skin cancer
management.50–52 In addition, further structuring of AK man-
agement, including explicit criteria for referral (e.g. AK not
responding to treatment, AK in immunosuppressed patients,
AK with the potential of SCC), may provide a substantive
potential to lower the burden in secondary care.19,53
In addition to efforts directed towards the general population
and primary care, this study also identified potential areas for
improvement in secondary care. Firstly, in the case of extensive
AKs (i.e. n ≥ 10), field treatment is recommended in national
and international guidelines.2,27 However, these guidelines
seem to be followed inconsistently, with only 32% of patients
with extensive AK receiving field treatment (although signifi-
cantly higher than in the group with mild AK). Secondly, the
majority of patients with AK seen by the dermatologists had at
least one follow-up visit, whereas the guidelines recommend
follow-up in secondary care only for high-risk patients (e.g.
those with immunosuppression).2,27 Comparable high follow-
up rates among patients with AK were observed in the U.K.52
These extensive follow-up rates by dermatologists for what
may be considered low-risk care have the potential for
overtreatment, and motives for this need to be explored.
A strength of this study is that multiple databases were anal-
ysed to obtain a comprehensive overview of AK-related care,
which has not been described before. The combination of a
population-based cohort and routine GP records is a unique
way to identify patients with AK who never visited a GP or
were not previously diagnosed in routine care, and to study
the occurrence of KCs related to AK extensiveness. Further-
more, by combining primary care and secondary care data-
bases, it provides a more comprehensive overview of the
management of patients with AK throughout the care process.
A limitation of routinely collected healthcare data is related
to what and how clinical data are recorded. An issue in GP
databases was, for example, that clinical AK severity or explicit
follow-up recommendations are usually not recorded. Further-
more, it is possible that a patient visits the GP for a different
(main) reason besides AK, which may result in lack of AK
registration in the GP record. However, by using these differ-
ent databases, the findings become more detailed and comple-
mentary. In healthcare claims data, it remains uncertain that
the claimed care was actually administered. Diagnoses in
claims data are less specific. Therefore, we may have included
patients with other more rare cutaneous premalignancies
(e.g. Bowen disease). This could have resulted in a greater
amount of treatments less specific to AK, or higher follow-up
visit rates. However, an algorithm to identify these patients
with AK showed a positive predictive value of up to 93%.
Finally, some aspects may be specific to the Dutch healthcare
system, and this may raise some concerns about the generaliz-
ability of our results. However, in many Western countries,
primary care is the point of entry in the healthcare system for
patients, and in many countries, some level of a gatekeeping
system is applied.45,52 Therefore, we believe that our observa-
tions could be applied to other countries as well. Regardless
of the type of healthcare system, AK is a high-volume condi-
tion and therefore comparable issues should be evaluated in
other countries to improve the efficiency of care.
In conclusion, AKs are a high-volume condition, with a sig-
nificant healthcare impact, but with a seemingly limited famil-
iarity with AK in the general population and possibly among
GPs this may lead to the suboptimal use of healthcare
resources. We identified areas in AK management that deviate
from (both national and international) primary care and sec-
ondary care guideline recommendations. Adequate risk differ-
entiation and improved guideline adherence in both primary
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and secondary care seem warranted to strengthen the vital role
of GPs in AK management and to optimize the utilization of
healthcare resources. To tailor the efforts needed, motives for
AK management diverging from current guidelines among
GPs and dermatologists need to be explored.
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